Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo across selected Latin American markets.
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.
From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and challenges.
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC).
The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and above.
Aptar and Macquarie's collaboration will evaluate how factors, including how formulation variables influence drug delivery with Aptar’s dry powder inhaler platform.
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Genialis and Inventia Life Science have partnered to enhance pancreatic cancer treatment testing and match them to the patients who are likely to benefit.
Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development.
All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.
BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical RLT asset in a deal worth up to $900m.
Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid tumours.
Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.
Sandoz and mAbxience have signed a licensing, development and commercialisation agreement for a proposed emicizumab biosimilar candidate for haemophilia A.
Psychedelics have become a clear priority for the FDA following an EO aimed at accelerating research and regulatory pathways to psychedelic treatments.
Cellares and GenomeFrontier Therapeutics are to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.
Gilead Sciences and the PAHO have signed an agreement to expedite access to the company’s twice-yearly lenacapavir injection for HIV prevention as PrEP across Latin America and the Caribbean.
Cheplapharm has entered into a strategic partnership to take over a portfolio of 20 mature medicines along with three manufacturing facilities globally from Sanofi.
The FDA has approved an update to the prescribing information for Amgen’s Imdelltra, cutting the recommended monitoring time for ES-SCLC patients after their first two infusions.
Cell and gene therapies are fuelling new possibilities for rare diseases, turning a field defined by unmet need into one of the industry’s most dynamic areas of innovation.
Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for DMD.
At ERS 2026, Generate: Biomedicines investigators presented pharmacodynamics and safety results from the company’s ongoing Phase I study (NCT07116889) evaluating GB-0895.
Gilead Sciences has opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines to treat challenging diseases.
Médunik Canada has entered into an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome.
At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.
